



Stockholm, 2019-10-23

PRESS RELEASE

QuiaPEG signs MTA with Chongqing PEG-BIO Biopharm Co., Ltd. for tailor-made linker evaluation

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or already approved drugs, so-called. biobetters. This is done on the basis of the company's own patent-protected technology platform, Uni-Qleaver®, which makes it possible to control a drug's release through a degradable chemical linker.

QuiaPEG and Chongqing PEG-BIO Biopharm Co., Ltd., (PEG-BIO), have today signed a so-called Material Transfer Agreement (MTA) which gives PEG-BIO the right to have a tailor-made linker evaluated from the Uni-Qleaver® library for a limited time together with a specific candidate substance in their pipeline. The aim is to improve the pharmacokinetic properties of the candidate substance by means of the tailor-made and releasable linker. For the right to evaluate a customized linker for a limited period, QuiaPEG receives a small amount of money. If the evaluation is successful, the parties agree to enter into negotiations on a license agreement.

"It is very satisfying that we are now signing an MTA with PEG-BIO, a growing and dynamic biotech company China. We see a great deal of interest from Chinese pharmaceutical companies, who want to develop more advanced drugs and need access to the kind of technology platform that QuiaPEG can provide. As previously communicated, a structured process is currently underway with a handful of Chinese pharmaceutical companies, who have expressed an interest in in-licensing our pharmaceutical project QPG-1029 for the Chinese market", says Marcus Bosson, CEO.

About Chongqing PEG-BIO Biopharm Co., Ltd

Chongqing PEG-BIO Biopharm Co., Ltd. is a national High-Tech enterprise established in 2013. PEG-BIO is a medium-sized Chinese biotech company with approximately 70 employees and a cGMP plant, which comprises of 1500 m² CDMO workshop and a 3000 m² R&D and Quality Center and 1000 m² office space, for the manufacture of biological drugs. The company recently raised multi-million

USD in venture capital for the development of drug candidates in diabetes, rare diseases, and cancer-related therapeutics.

For further information contact:

Marcus Bosson

CEO

Phone: +46 (0) 70 693 12 53

e-mail: marcus.bosson@quiapeg.com

www.quiapeg.com

This information is such that QuiaPEG Pharmaceuticals Holding AB (publ) is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on 23 October, 2019, through the contact of the above contact person.